Holen Sie sich die Stockscreener-App
76.53
0.17%
0.13
Schlusskurs vom Vortag:
$76.40
Offen:
$76.77
24-Stunden-Volumen:
548.59K
Relative Volume:
0.25
Marktkapitalisierung:
$14.75B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-31.76
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
+3.39%
1M Leistung:
+7.80%
6M Leistung:
+72.17%
1J Leistung:
+168.24%
1-Tages-Spanne:
$76.38
$77.32
1-Wochen-Bereich:
$73.48
$78.44
52-Wochen-Spanne:
$27.23
$78.44
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
76.53 | 14.72B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Has More Room To Run (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month HighHere's Why - MarketBeat
BridgeBio Pharma stock hits all-time high at $77.32 By Investing.com - Investing.com Nigeria
BridgeBio Pharma stock hits all-time high at $77.32 - Investing.com
BridgeBio Pharma Earnings Notes - Trefis
Assenagon Asset Management S.A. Trims Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Why global investors buy BridgeBio Pharma Inc. (2CL) stockJuly 2025 Fed Impact & Low Risk Entry Point Guides - Улправда
Will BridgeBio Pharma Inc. stock benefit from commodity pricesTrade Entry Report & Real-Time Sentiment Analysis - Улправда
Why BridgeBio Pharma Inc. stock could rally in 20252025 Year in Review & Safe Investment Capital Preservation Plans - ulpravda.ru
First Week of August 2026 Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
What hedge fund activity signals for BridgeBio Pharma Inc. stock2025 Big Picture & Reliable Entry Point Trade Alerts - Улправда
Gains Recap: Why BridgeBio Pharma Inc. stock could rally in 2025Analyst Upgrade & Weekly Top Stock Performers List - Улправда
Will BridgeBio Pharma Inc. stock maintain growth story2025 Market Trends & Low Risk Growth Stock Ideas - Улправда
BridgeBio Pharma Sees Unusually Large Options Volume (NASDAQ:BBIO) - MarketBeat
Layoff Watch: What hedge fund activity signals for BridgeBio Pharma Inc. stockJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Path To Profitability - 富途牛牛
Hypoparathyroidism Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing - marketscreener.com
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 30,011 Shares - MarketBeat
Pres Trimarchi Acquires 11,174 Of Bridgebio Pharma Inc [BBIO] - TradingView — Track All Markets
BridgeBio Pharma (BBIO) CEO discloses RSU vesting and stock sales - Stock Titan
BridgeBio Pharma (NASDAQ: BBIO) CFO notes 13,826 shares withheld for taxes - Stock Titan
BridgeBio Pharma (BBIO) CAO discloses RSU tax share withholding - Stock Titan
BridgeBio Pharma (BBIO) Receives Maintained Rating with Raised P - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighTime to Buy? - MarketBeat
Is the Market Bullish or Bearish on BridgeBio Pharma Inc? - Benzinga
Castleark Management LLC Cuts Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Gilder Gagnon Howe & Co. LLC Boosts Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Eventide Asset Management LLC Decreases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha
BridgeBio Pharma stock hits all-time high at 75.13 USD - Investing.com
BridgeBio Pharma stock hits all-time high at 75.13 USD By Investing.com - Investing.com Australia
BridgeBio Pharma (BBIO) Valuation After Attruby-Driven Earnings Beat and Renewed Analyst Support - Yahoo Finance
What Recent Clinical Wins Mean For BridgeBio Pharma’s Evolving Growth Story - Yahoo Finance
Frontier Capital Management Co. LLC Sells 233,538 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bernstein initiates BridgeBio Pharma stock coverage with Outperform rating By Investing.com - Investing.com Canada
Check out BridgeBio Pharma's stock price (1BBIO-IT) in real time - CNBC
Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target - marketscreener.com
This Option Care Health Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - Benzinga
HighVista Strategies LLC Increases Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bernstein Initiates Coverage of BridgeBio Pharma (BBIO) with Outperform Recommendation - Nasdaq
BBIO Gets "Outperform" Rating as Bernstein Initiates Coverage | - GuruFocus
Federated Hermes Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio (BBIO) Unveils Promising Preclinical Data for Cancer T - GuruFocus
BridgeBio (BBIO) Unveils Promising Preclinical Data for Cancer Treatment - GuruFocus
Apuli Maricel, chief accounting officer, sells $148k in BridgeBio (BBIO) - Investing.com Canada
This Hot Biotech Stock Just Set New All-Time Highs - Barchart.com
BridgeBio Pharma (NASDAQ:BBIO) CAO Sells $148,520.00 in Stock - MarketBeat
Insider Sell Alert: Maricel Apuli Sells 2,000 Shares of BridgeBi - GuruFocus
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):